Management of the COPD Patient with Comorbidities: An Experts Recommendation Document

References

• Organización Mundial de la Salud (OMS). Descriptive note : chronic obstructive pulmonary disease (COPD). 2016, November. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed January 2017.
   Google Scholar
• MiravitllesM, SorianoJB, Garcia-RioF, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863–868. doi:10.1136/thx.2009.11572519553233
   PubMed Web of Science ®Google Scholar
• Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) – guía Española de la EPOC (GesEPOC). Versión 2017 [Clinical Practice Guideline for the Diagnosis and Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) – Spanish Guideline for COPD (GesEPOC). 2017 version]. Arch Bronconeumol. 2017;53(Suppl 1):2–64. Spanish.
   Google Scholar
• Díez-ManglanoJ, López-GarcíaF. Protocolos: manejo Diagnóstico y Terapéutico de las Comorbilidades en la EPOC [Protocols: Diagnostic and Therapeutic management of Comorbidities in COPD]. Sociedad Española de Medicina Interna (SEMI) y Elsevier SL. 2014;1–259. Spanish.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the global strategy for the diagnosis, management and prevention of COPD. 2017 Available from: http://goldcopd.org. Accessed 316, 2020.
   Google Scholar
• SinDD, AnthonisenNR, SorianoJB, AgustiAG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–1257. doi:10.1183/09031936.0013380517138679
   PubMed Web of Science ®Google Scholar
• SmithMC, WrobelJP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD25210449
   PubMed Web of Science ®Google Scholar
• BrookR. The RAND/UCLA Appropriateness Method. Rockville, MD: AHCPR Pub; 1994.
   Google Scholar
• Scottish Intercollegiate Guidelines Network. A Guideline Developers’ Handbook (Publication Nº 50). Edinburgh: SIGN; 2001 Disponible en: http://www.sign.ac.uk/guidelines/fulltext/50/index.html. Accessed 316, 2020.
   Google Scholar
• Oxford Centre for Evidence-Based Medicine. Levels of Evidence Document. (Consultado Enero 2017). 2011 Disponible en: http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf. Accessed 316, 2020.
   Google Scholar
• ScholsAM, BuurmanWA, Staal van den BrekelAJ, DentenerMA, WoutersEF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51(8):819–824. doi:10.1136/thx.51.8.8198795671
   PubMed Web of Science ®Google Scholar
• Almagro MenaP, Rodríguez CarballeiraM. Afectación extrapulmonar en la EPOC.¿ Qué es relevante y cómo debemos evaluarla [Extrapulmonary involvement in COPD: what is relevant and how should we evaluate it?] Med Clin (Barc). 2011;18–23. Spanish.
   Google Scholar
• Garcia-RioF, SorianoJB, MiravitllesM, et al. Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease. PLoS One. 2014;9(8):e105220. doi:10.1371/journal.pone.010522025153331
   PubMed Web of Science ®Google Scholar
• SteutenLM, CreutzbergEC, VrijhoefHJ, WoutersEF. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J. 2006;15(2):84–91. doi:10.1016/j.pcrj.2005.09.00116701766
   PubMedGoogle Scholar
• FranssenFM, O’DonnellDE, GoossensGH, BlaakEE, ScholsAM. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63(12):1110–1117. doi:10.1136/thx.2007.08682719020276
   PubMed Web of Science ®Google Scholar
• CecereLM, LittmanAJ, SlatoreCG, et al. Obesity and COPD: associated symptoms, health-related quality of life, and medication use. COPD. 2011;8(4):275–284. doi:10.3109/15412555.2011.58666021809909
   PubMedGoogle Scholar
• VozorisNT, O’DonnellDE. Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. Can Respir J. 2012;19(3):e18–24. doi:10.1155/2012/73261822679617
   PubMed Web of Science ®Google Scholar
• CurtisJR, WestfallAO, AllisonJ, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426. doi:10.1002/(ISSN)1529-013116739208
   PubMed Web of Science ®Google Scholar
• YuanL, DaiX, YangM, CaiQ, ShaoN. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:1477–1483. doi:10.2147/COPD.S10637027418821
   PubMed Web of Science ®Google Scholar
• SavaF, LavioletteL, BernardS, BretonMJ, BourbeauJ, MaltaisF. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med. 2010;10(1):55. doi:10.1186/1471-2466-10-5521054892
   PubMed Web of Science ®Google Scholar
• RamachandranK, McCuskerC, ConnorsM, ZuwallackR, LahiriB. The influence of obesity on pulmonary rehabilitation outcomes in patients with COPD. Chron Respir Dis. 2008;5(4):205–209. doi:10.1177/147997230809671119029231
   PubMedGoogle Scholar
• SabinoPG, SilvaBM, BrunettoAF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. Clinics (Sao Paulo). 2010;65(6):599–605. doi:10.1590/S1807-5932201000060000720613936
   PubMed Web of Science ®Google Scholar
• FarsangC, KissI, TykarskiA, NarkiewiczK. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). Eur Soc Hypertension Sci Newsletter. 2016;17:62.
   Google Scholar
• SchonhoferB, WenzelM, GeibelM, KohlerD. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med. 1998;26(11):1824–1828. doi:10.1097/00003246-199811000-000229824074
   PubMed Web of Science ®Google Scholar
• MillerJ, EdwardsLD, AgustiA, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. doi:10.1016/j.rmed.2013.05.00123791463
   PubMed Web of Science ®Google Scholar
• SchnabelE, NowakD, BrascheS, WichmannHE, HeinrichJ. Association between lung function, hypertension and blood pressure medication. Respir Med. 2011;105(5):727–733. doi:10.1016/j.rmed.2010.12.02321276721
   PubMed Web of Science ®Google Scholar
• WakabayashiK, GonzalezMA, DelhayeC, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010;106(3):305–309. doi:10.1016/j.amjcard.2010.03.02620643237
   PubMed Web of Science ®Google Scholar
• WorthH, ChungKF, FelserJM, HuH, RueeggP. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571–579. doi:10.1016/j.rmed.2010.11.02721227674
   PubMed Web of Science ®Google Scholar
• WiseRA, AnzuetoA, CottonD, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa130334223992515
   PubMed Web of Science ®Google Scholar
• WhiteWB, CookeGE, KoweyPR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758–765. doi:10.1378/chest.12-233223412642
   PubMed Web of Science ®Google Scholar
• Di DanieleN. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. Pulm Pharmacol Ther. 2015;35:1–7. doi:10.1016/j.pupt.2015.09.00426363278
   PubMed Web of Science ®Google Scholar
• ManciniGB, EtminanM, ZhangB, LevesqueLE, FitzGeraldJM, BrophyJM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560. doi:10.1016/j.jacc.2006.04.03916781387
   PubMed Web of Science ®Google Scholar
• SalpeterS, OrmistonT, SalpeterE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:Cd003566.
   Google Scholar
• CazzolaM, NoscheseP, D’AmatoG, MateraMG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002;121(1):230–241. doi:10.1378/chest.121.1.23011796456
   PubMed Web of Science ®Google Scholar
• CazzolaM, NoscheseP, D’AmatoM, D’AmatoG. Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. Chest. 2000;118(5):1322–1326. doi:10.1378/chest.118.5.132211083681
   PubMed Web of Science ®Google Scholar
• DransfieldMT, RoweSM, JohnsonJE, BaileyWC, GeraldLB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301–305. doi:10.1136/thx.2007.08189317951276
   PubMed Web of Science ®Google Scholar
• RuttenFH, ZuithoffNP, HakE, GrobbeeDE, HoesAW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–887. doi:10.1001/archinternmed.2010.11220498416
   PubMed Web of Science ®Google Scholar
• HillNS. Fluid and electrolyte considerations in diuretic therapy for hypertensive patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(1):129–133. doi:10.1001/archinte.1986.003601301590222867747
   PubMedGoogle Scholar
• ManninoDM, ThornD, SwensenA, HolguinF. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. doi:10.1183/09031936.0001240818579551
   PubMed Web of Science ®Google Scholar
• AlmagroP, LopezF, CabreraFJ, et al. Comorbilidades en pacientes hospitalizados por enfermedad pulmonar obstructiva crónica. Análisis comparativo de los estudios ECCO y ESMI [Comorbidities in hospitalized patients for chronic obstructive pulmonary disease. Comparative analysis of the ECCO and ESMI studies]. Rev Clin Esp. 2012;212(6):281–286. doi:10.1016/j.rce.2012.02.014. Spanish.22521437
   PubMed Web of Science ®Google Scholar
• EhrlichSF, QuesenberryCP Jr., Van Den EedenSK, ShanJ, FerraraA. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55–60. doi:10.2337/dc09-088019808918
   PubMed Web of Science ®Google Scholar
• WackerME, HungerM, KarraschS, et al. Health-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age population. BMC Pulm Med. 2014;14:134. doi:10.1186/1471-2466-14-13425107380
   PubMed Web of Science ®Google Scholar
• JansonC, MarksG, BuistS, et al. The impact of COPD on health status: findings from the BOLD study. Eur Respir J. 2013;42(6):1472–1483. doi:10.1183/09031936.0015371223722617
   PubMed Web of Science ®Google Scholar
• Lopez VarelaMV, Montes de OcaM, HalbertRet al,. Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study. Arch Bronconeumol. 2013;49(11):468–474. doi:10.1016/j.arbr.2013.09.00923856439
   PubMed Web of Science ®Google Scholar
• KoskelaJ, KilpelainenM, KupiainenH, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med. 2014;14:102. doi:10.1186/1471-2466-14-10224946786
   PubMed Web of Science ®Google Scholar
• PutchaN, PuhanMA, HanselNN, DrummondMB, BoydCM. Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001–2008. COPD. 2013;10(3):324–332. doi:10.3109/15412555.2012.74496323713595
   PubMedGoogle Scholar
• KinneyGL, Black-ShinnJL, WanES, et al. Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care. 2014;37(2):389–395. doi:10.2337/dc13-143524026562
   PubMed Web of Science ®Google Scholar
• BakerEH, JanawayCH, PhilipsBJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61(4):284–289. doi:10.1136/thx.2005.05102916449265
   PubMed Web of Science ®Google Scholar
• BurtMG, RobertsGW, Aguilar-LozaNR, FrithP, StranksSN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96(6):1789–1796. doi:10.1210/jc.2010-272921411550
   PubMed Web of Science ®Google Scholar
• ChakrabartiB, AngusRM, AgarwalS, LaneS, CalverleyPM. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax. 2009;64(10):857–862. doi:10.1136/thx.2008.10698919454410
   PubMed Web of Science ®Google Scholar
• YoungRP, HopkinsRJ, ChristmasT, BlackPN, MetcalfP, GambleGD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380–386. doi:10.1183/09031936.0014420819196816
   PubMed Web of Science ®Google Scholar
• CazzolaM, BettoncelliG, SessaE, CricelliC, BiscioneG. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(2):112–119. doi:10.1159/00028188020134148
   PubMed Web of Science ®Google Scholar
• GudmundssonG, UlrikCS, GislasonT, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis. 2012;7:571–576. doi:10.2147/COPD.S3446623055707
   PubMed Web of Science ®Google Scholar
• van den BorstB, GoskerHR, ZeegersMP, ScholsAM. Pulmonary function in diabetes: a metaanalysis. Chest. 2010;138(2):393–406. doi:10.1378/chest.09-262220348195
   PubMed Web of Science ®Google Scholar
• Wood-BakerRR, GibsonPG, HannayM, WaltersEH, WaltersJA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;1:Cd001288.
   Google Scholar
• SuissaS, KezouhA, ErnstP. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–1006. doi:10.1016/j.amjmed.2010.06.01920870201
   PubMed Web of Science ®Google Scholar
• O’ByrnePM, RennardS, GersteinH, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106(11):1487–1493. doi:10.1016/j.rmed.2012.07.01122902134
   PubMed Web of Science ®Google Scholar
• WoutersEF, BredenbrokerD, TeichmannP, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(9):E1720–1725. doi:10.1210/jc.2011-288622723325
   PubMed Web of Science ®Google Scholar
• Garcia-OlmosL, AlberquillaA, AyalaV, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract. 2013;14:11. doi:10.1186/1471-2296-14-1123324308
   PubMed Web of Science ®Google Scholar
• de Lucas-ramosP, Izquierdo-AlonsoJL, Rodriguez-Gonzalez MoroJM, et al. [Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study]. Arch Bronconeumol. 2008;44(5):233–238. doi:10.1157/1311993718448013
   PubMed Web of Science ®Google Scholar
• de Lucas-ramosP, Izquierdo-AlonsoJL, Rodriguez-Gonzalez MoroJM, FrancesJF, LozanoPV, Bellon-CanoJM. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012;7:679–686. doi:10.2147/COPD.S3622223055717
   PubMed Web of Science ®Google Scholar
• BasiliS, FerroniP, VieriM, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147(2):249–252. doi:10.1016/S0021-9150(99)00192-610559510
   PubMed Web of Science ®Google Scholar
• EttingerWH, KlinefelterHF, KwiterovitchPO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2–3):167–172. doi:10.1016/0021-9150(87)90117-13493784
   PubMed Web of Science ®Google Scholar
• HooperPL, WooW, ViscontiL, PathakDR. Terbutaline raises high-density-lipoprotein-cholesterol levels. N Engl J Med. 1981;305(24):1455–1457. doi:10.1056/NEJM1981121030524066946283
   PubMed Web of Science ®Google Scholar
• de Miguel DiezJ, Chancafe MorganJ, Jimenez GarciaR. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305–312. doi:10.2147/COPD.S3123623847414
   PubMed Web of Science ®Google Scholar
• TsiligianniIG, KosmasE, Van der MolenT, TzanakisN. Managing comorbidity in COPD: a difficult task. Curr Drug Targets. 2013;14(2):158–176. doi:10.2174/138945011131402000423256716
   PubMed Web of Science ®Google Scholar
• LeeTM, LinMS, ChangNC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–535. doi:10.1016/j.amjcard.2007.09.10218312772
   PubMed Web of Science ®Google Scholar
• CrinerGJ, ConnettJE, AaronSD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi:10.1056/NEJMoa140308624836125
   PubMed Web of Science ®Google Scholar
• ChogtuB, KuriachanS, MagazineR, et al. A prospective, randomized study: evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Indian J Pharmacol. 2016;48(5):503–508. doi:10.4103/0253-7613.19072127721534
   PubMed Web of Science ®Google Scholar
• IngebrigtsenTS, MarottJL, NordestgaardBG, LangeP, HallasJ, VestboJ. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40. doi:10.1136/thoraxjnl-2014-20579525349333
   PubMed Web of Science ®Google Scholar
• HuangCC, ChanWL, ChenYC, et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin Ther. 2011;33(10):1365–1370. doi:10.1016/j.clinthera.2011.08.01021962452
   PubMed Web of Science ®Google Scholar
• AjmeraM, ShenC, SambamoorthiU. Association between statin medications and COPD-specific outcomes: a real-world observational study. Drugs Real World Outcomes. 2017;4(1):9–19. doi:10.1007/s40801-016-0101-627943058
   PubMedGoogle Scholar
• LahousseL, LothDW, JoosGF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013;26(2):212–217. doi:10.1016/j.pupt.2012.10.00823142156
   PubMed Web of Science ®Google Scholar
• RaymakersAJN, SadatsafaviM, SinDD, De VeraMA, LyndLD. The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study. Chest. 2017;152(3):486–493. doi:10.1016/j.chest.2017.02.00228202342
   PubMed Web of Science ®Google Scholar
• CitgezE, van der PalenJ, Koehorst-Ter HuurneK, MovigK, van der ValkP, Brusse-KeizerM. Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study. BMJ Open Respir Res. 2016;3(1):e000142. doi:10.1136/bmjresp-2016-000142
   PubMedGoogle Scholar
• ZhangW, ZhangY, LiCW, JonesP, WangC, FanY. Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest. 2017;152(6):1159–1168. doi:10.1016/j.chest.2017.08.01528847550
   PubMed Web of Science ®Google Scholar
• BhattSP, DransfieldMT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013;162(4):237–251. doi:10.1016/j.trsl.2013.05.00123727296
   PubMed Web of Science ®Google Scholar
• AlmagroP, Lopez GarciaF, CabreraFJ, et al. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. Respir Med. 2010;104(2):253–259. doi:10.1016/j.rmed.2009.09.01919879744
   PubMed Web of Science ®Google Scholar
• AlmagroP, CabreraFJ, DiezJ, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126–1133. doi:10.1378/chest.11-241323303399
   PubMed Web of Science ®Google Scholar
• FonarowGC, HeywoodJT, HeidenreichPA, LopatinM, YancyCW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153(6):1021–1028. doi:10.1016/j.ahj.2007.03.01217540205
   PubMed Web of Science ®Google Scholar
• MentzRJ, FiuzatM, WojdylaDM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail. 2012;14(4):395–403. doi:10.1093/eurjhf/hfs00922302663
   PubMed Web of Science ®Google Scholar
• MatamisD, TsagouriasM, PapathanasiouA, et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care. 2014;29(2):315.e317–314. doi:10.1016/j.jcrc.2013.11.011
   PubMed Web of Science ®Google Scholar
• SuzukiT, LyonA, SaggarR, et al. Editor’s choice-biomarkers of acute cardiovascular and pulmonary diseases. Eur Heart J Acute Cardiovasc Care. 2016;5(5):416–433. doi:10.1177/204887261665230927221957
   PubMed Web of Science ®Google Scholar
• PavasiniR, TavazziG, BiscagliaS, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117–126. doi:10.1177/147997231667439327956645
   PubMed Web of Science ®Google Scholar
• CavaillesA, Brinchault-RabinG, DixmierA, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475. doi:10.1183/09059180.0000861224293462
   PubMedGoogle Scholar
• LeeH, JhunBW, ChoJ, et al. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity. Int J Chron Obstruct Pulmon Dis. 2017;12:3301–3310. doi:10.2147/COPD29180860
   PubMed Web of Science ®Google Scholar
• HenochI, StrangS, LofdahlCG, Ekberg-JanssonA. Health-related quality of life in a nationwide cohort of patients with COPD related to other characteristics. Eur Clin Respir J. 2016;3(1):31459. doi:10.3402/ecrj.v3.3145927238360
   PubMed Web of Science ®Google Scholar
• JacobsDM, NoyesK, ZhaoJ, et al. Early hospital readmissions after an acute exacerbation of chronic obstructive pulmonary disease in the nationwide readmissions database. Ann Am Thorac Soc. 2018;15(7):837–845. doi:10.1513/AnnalsATS.201712-913OC29611719
   PubMed Web of Science ®Google Scholar
• ShahT, ChurpekMM, Coca PerraillonM, KonetzkaRT. Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. Chest. 2015;147(5):1219–1226. doi:10.1378/chest.14-218125539483
   PubMed Web of Science ®Google Scholar
• AlmagroP, CalboE, Ochoa de EchaguenA, et al. Mortality after hospitalization for COPD. Chest. 2002;121(5):1441–1448. doi:10.1378/chest.121.5.144112006426
   PubMed Web of Science ®Google Scholar
• TavazziL, SwedbergK, KomajdaM, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170(2):182–188. doi:10.1016/j.ijcard.2013.10.06824225201
   PubMed Web of Science ®Google Scholar
• CanepaM, Straburzynska-MigajE, DrozdzJ, et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(1):100–110. doi:10.1002/ejhf.96428949063
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, BrookRD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• SampJC, JooMJ, SchumockGT, CalipGS, PickardAS, LeeTA. Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting beta2-agonist combined with a long-acting muscarinic or inhaled corticosteroid. Ann Pharmacother. 2017;51(11):945–953. doi:10.1177/106002801771971628677404
   PubMed Web of Science ®Google Scholar
• RodrigoGJ, PriceD, AnzuetoA, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD28360514
   PubMed Web of Science ®Google Scholar
• RoversiS, FabbriLM, SinDD, HawkinsNM, AgustiA. Chronic obstructive pulmonary disease and cardiac diseases. an urgent need for integrated care. Am J Respir Crit Care Med. 2016;194(11):1319–1336. doi:10.1164/rccm.201604-0690SO27589227
   PubMed Web of Science ®Google Scholar
• LainscakM, PodbregarM, KovacicD, RozmanJ, von HaehlingS. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105(Suppl 1):S44–49. doi:10.1016/S0954-6111(11)70010-522015086
   PubMed Web of Science ®Google Scholar
• CoiroS, GirerdN, RossignolP, et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the high-risk myocardial infarction database initiative. Eur J Heart Fail. 2017;19(2):271–279. doi:10.1002/ejhf.64727774703
   PubMed Web of Science ®Google Scholar
• DuQ, SunY, DingN, LuL, ChenY. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048.25427000
   PubMed Web of Science ®Google Scholar
• EtminanM, JafariS, CarletonB, FitzGeraldJM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(1):48. doi:10.1186/1471-2466-12-4822947076
   PubMed Web of Science ®Google Scholar
• MiravitllesM, Soler-CatalunaJJ, CalleM, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.01828477954
   PubMed Web of Science ®Google Scholar
• PutchaN, DrummondMB, WiseRA, HanselNN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575–591. doi:10.1055/s-0000007526238643
   PubMed Web of Science ®Google Scholar
• MapelDW, DedrickD, DavisK. Trends and cardiovascular co-morbidities of COPD patients in the veterans administration medical system, 1991–1999. COPD. 2005;2(1):35–41. doi:10.1081/COPD-20005067117136959
   PubMedGoogle Scholar
• MullerovaH, AgustiA, ErqouS, MapelDW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. doi:10.1378/chest.12-284723722528
   PubMed Web of Science ®Google Scholar
• MapelD. Insights into COPD comorbidities from the OLIN study and other large databases. COPD. 2011;8(6):397–399. doi:10.3109/15412555.2011.63655522149398
   PubMedGoogle Scholar
• ChenW, ThomasJ, SadatsafaviM, FitzGeraldJM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-626208998
   PubMed Web of Science ®Google Scholar
• Soriano OrtizJB, AlmagroP, Sauleda RoigJ. [Causes of mortality in COPD]. Arch Bronconeumol. 2009;45(Suppl 4):8–13. doi:10.1016/S0300-2896(09)72857-120116743
   PubMedGoogle Scholar
• Miguel-DíezJ, Carrasco-GarridoP, Rejas-GutierrezJ, et al. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings. BMC Cardiovasc Disord. 2010;10(1):8. doi:10.1186/1471-2261-10-820167091
   PubMed Web of Science ®Google Scholar
• Black-ShinnJL, KinneyGL, WiseAL, et al. Cardiovascular disease is associated with COPD severity and reduced functional status and quality of life. COPD. 2014;11(5):546–551. doi:10.3109/15412555.2014.89802924831864
   PubMedGoogle Scholar
• PatelARC, DonaldsonGC, MackayAJ, WedzichaJA, HurstJR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141(4):851–857. doi:10.1378/chest.11-085321940771
   PubMed Web of Science ®Google Scholar
• DalalAA, ShahM, LunacsekO, HananiaNA. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011;105(10):1516–1522. doi:10.1016/j.rmed.2011.04.00521684731
   PubMed Web of Science ®Google Scholar
• PatelAR, KowlessarBS, DonaldsonGC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091–1099. doi:10.1164/rccm.201306-1170OC24033321
   PubMed Web of Science ®Google Scholar
• CampoG, PavasiniR, MalagùM, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29(2):147–157. doi:10.1007/s10557-014-6569-y25645653
   PubMed Web of Science ®Google Scholar
• CalverleyPM, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• ContoliM, CampoG, PavasiniR, et al. Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. Eur J Intern Med. 2018;47:82–86. doi:10.1016/j.ejim.2017.08.01628821412
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• VestboJ, FabbriL, PapiA, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230. doi:10.1183/13993003.01230-201830209195
   PubMed Web of Science ®Google Scholar
• XiaN, WangH, NieX. Inhaled long-acting beta2-agonists do not increase fatal cardiovascular adverse events in COPD: a meta-analysis. PLoS One. 2015;10(9):e0137904. doi:10.1371/journal.pone.013790426378450
   PubMed Web of Science ®Google Scholar
• CazzolaM, CalzettaL, MateraMG, MuscoliS, RoglianiP, RomeoF. Chronic obstructive pulmonary disease and coronary disease: cOPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med. 2015;109(8):1019–1025. doi:10.1016/j.rmed.2015.05.02126111914
   PubMed Web of Science ®Google Scholar
• MortensenEM, CopelandLA, PughMJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10(1):45. doi:10.1186/1465-9921-10-4519493329
   PubMed Web of Science ®Google Scholar
• StefanMS, RothbergMB, PriyaA, PekowPS, AuDH, LindenauerPK. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67(11):977–984. doi:10.1136/thoraxjnl-2012-20194522941975
   PubMed Web of Science ®Google Scholar
• PavasiniR, BiscagliaS, d’AscenzoF, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016;13(4):509–514. doi:10.3109/15412555.2015.109962026678708
   PubMedGoogle Scholar
• Houben-WilkeS, JorresRA, BalsR, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences-comorbidities network study. Am J Respir Crit Care Med. 2017;195(2):189–197. doi:10.1164/rccm.201602-0354OC27532739
   PubMed Web of Science ®Google Scholar
• AzizF, LehmanEB. Preexisting conditions determine the occurrence of unplanned readmissions after procedures for treatment of peripheral arterial disease. Ann Vasc Surg. 2018;50:60–72. doi:10.1016/j.avsg.2018.01.07529481929
   PubMed Web of Science ®Google Scholar
• WaschkiB, KirstenA, HolzO, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–342. doi:10.1378/chest.10-252121273294
   PubMed Web of Science ®Google Scholar
• PepinJL, CockcroftJR, MidwinterD, SharmaS, RubinDB, AndreasS. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest. 2014;146(6):1521–1530. doi:10.1378/chest.13-285925058845
   PubMed Web of Science ®Google Scholar
• van GestelYR, HoeksSE, SinDD, et al. Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:177–183. doi:10.2147/copd.s551119516916
   PubMedGoogle Scholar
• MiraultT, GalloulaA, CambouJP, et al. Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: the COPART registry. Medicine (Baltimore). 2017;96(5):e5916. doi:10.1097/MD.000000000000591628151868
   PubMed Web of Science ®Google Scholar
• Gerhard-HermanMD, GornikHL, BarrettC, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017;135(12). e686-e725. doi:10.1161/CIRCULATIONAHA.117.027305
   Web of Science ®Google Scholar
• OnishiK. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017;70(2):128–134. doi:10.1016/j.jjcc.2017.03.00128325523
   PubMed Web of Science ®Google Scholar
• BarrettTW, SelfWH, JenkinsCA, et al. Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation. Am J Cardiol. 2013;112(9):1410–1416. doi:10.1016/j.amjcard.2013.07.00523972347
   PubMed Web of Science ®Google Scholar
• SteerJ, GibsonJ, BourkeSC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970–976. doi:10.1136/thoraxjnl-2012-20210322895999
   PubMed Web of Science ®Google Scholar
• EchevarriaC, SteerJ, Heslop-MarshallK, et al. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. Thorax. 2016;71(2):133–140. doi:10.1136/thoraxjnl-2015-20777526769015
   PubMed Web of Science ®Google Scholar
• SangwanV, ChaudhryD, DyspneaMR, EosinopeniaC. Acidemia and atrial fibrillation score and BAP-65 score, tools for prediction of mortality in acute exacerbations of chronic obstructive pulmonary disease: a comparative pilot study. Indian J Crit Care Med. 2017;21(10):671–677. doi:10.4103/ijccm.IJCCM_148_1729142379
   PubMed Web of Science ®Google Scholar
• GoudisCA. Chronic obstructive pulmonary disease and atrial fibrillation: an unknown relationship. J Cardiol. 2017;69(5):699–705. doi:10.1016/j.jjcc.2016.12.01328188041
   PubMed Web of Science ®Google Scholar
• KirchhofP, BenussiS, KotechaD, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–e88.27663299
   PubMed Web of Science ®Google Scholar
• AnthonisenNR, ConnettJE, EnrightPL, ManfredaJ. Lung health study research G. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med. 2002;166(3):333–339. doi:10.1164/rccm.211009312153966
   PubMed Web of Science ®Google Scholar
• OgaleSS, LeeTA, AuDH, BoudreauDM, SullivanSD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13–19. doi:10.1378/chest.08-236719363211
   PubMed Web of Science ®Google Scholar
• WilcheskyM, ErnstP, BrophyJM, PlattRW, SuissaS. Bronchodilator use and the risk of arrhythmia in COPD: part 1: saskatchewan cohort study. Chest. 2012;142(2):298–304. doi:10.1378/chest.10-249922871755
   PubMed Web of Science ®Google Scholar
• HuertaC, LanesSF, Garcia RodriguezLA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005;16(3):360–366. doi:10.1097/01.ede.0000158743.90664.a715824553
   PubMed Web of Science ®Google Scholar
• WilcheskyM, ErnstP, BrophyJM, PlattRW, SuissaS. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305–311. doi:10.1378/chest.11-159722871756
   PubMed Web of Science ®Google Scholar
• van der HooftCS, HeeringaJ, BrusselleGG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–1020. doi:10.1001/archinte.166.9.101616682576
   PubMedGoogle Scholar
• WillgossTG, YohannesAM. Anxiety disorders in patients with COPD: a systematic review. Respir Care. 2013;58(5):858–866. doi:10.4187/respcare.0186222906542
   PubMed Web of Science ®Google Scholar
• AtlantisE, FaheyP, CochraneB, SmithS. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013;144(3):766–777. doi:10.1378/chest.12-191123429910
   PubMed Web of Science ®Google Scholar
• von LeupoldtA, KennK. The psychology of chronic obstructive pulmonary disease. Curr Opin Psychiatry. 2013;26(5):458–463. doi:10.1097/YCO.0b013e328363c1fc23867658
   PubMed Web of Science ®Google Scholar
• QianJ, Simoni-WastilaL, RattingerGB, et al. Association between depression and maintenance medication adherence among Medicare beneficiaries with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2014;29(1):49–57. doi:10.1002/gps.v29.123606418
   PubMed Web of Science ®Google Scholar
• PapaioannouAI, BartziokasK, TsikrikaS, et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J. 2013;41(4):815–823. doi:10.1183/09031936.0001311222878874
   PubMed Web of Science ®Google Scholar
• LaurinC, MoullecG, BaconSL, LavoieKL. Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med. 2012;185(9):918–923. doi:10.1164/rccm.201105-0939PP22246177
   PubMed Web of Science ®Google Scholar
• CafarellaPA, EffingTW, UsmaniZA, FrithPA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology. 2012;17(4):627–638. doi:10.1111/j.1440-1843.2012.02148.x22309179
   PubMed Web of Science ®Google Scholar
• KunikME, RoundyK, VeazeyC, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205–1211. doi:10.1378/chest.127.4.120515821196
   PubMed Web of Science ®Google Scholar
• NgTP, NitiM, TanWC, CaoZ, OngKC, EngP. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–67. doi:10.1001/archinte.167.1.6017210879
   PubMed Web of Science ®Google Scholar
• MaurerJ, RebbapragadaV, BorsonS, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43s–56s. doi:10.1378/chest.08-034218842932
   PubMed Web of Science ®Google Scholar
• EisnerMD, BlancPD, YelinEH, et al. Influence of anxiety on health outcomes in COPD. Thorax. 2010;65(3):229–234. doi:10.1136/thx.2009.12620120335292
   PubMed Web of Science ®Google Scholar
• BakasT, McLennonSM, CarpenterJS, et al. Systematic review of health-related quality of life models. Health Qual Life Outcomes. 2012;10(1):134. doi:10.1186/1477-7525-10-13423158687
   PubMed Web of Science ®Google Scholar
• BlakemoreA, DickensC, GuthrieE, et al. Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:501–512. doi:10.2147/COPD24876770
   PubMed Web of Science ®Google Scholar
• DalalAA, ShahM, LunacsekO, HananiaNA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011;8(4):293–299. doi:10.3109/15412555.2011.58665921827298
   PubMedGoogle Scholar
• SinghG, ZhangW, KuoYF, SharmaG. Association of psychological disorders with 30-day readmission rates in patients with COPD. Chest. 2016;149(4):905–915. doi:10.1378/chest.15-044926204260
   PubMed Web of Science ®Google Scholar
• ZwerinkM, Brusse-KeizerM, van der ValkPD, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD002990.
   PubMed Web of Science ®Google Scholar
• SpitzerC, GlaserS, GrabeHJ, et al. Mental health problems, obstructive lung disease and lung function: findings from the general population. J Psychosom Res. 2011;71(3):174–179. doi:10.1016/j.jpsychores.2011.03.00521843753
   PubMed Web of Science ®Google Scholar
• CoventryPA, BowerP, KeyworthC, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013;8(4):e60532. doi:10.1371/journal.pone.006053223585837
   PubMed Web of Science ®Google Scholar
• AbramsTE, Vaughan-SarrazinM, Van der WegMW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics. 2011;52(5):441–449. doi:10.1016/j.psym.2011.03.00521907063
   PubMed Web of Science ®Google Scholar
• TselebisA, KosmasE, BratisD, et al. Prevalence of alexithymia and its association with anxiety and depression in a sample of Greek chronic obstructive pulmonary disease (COPD) outpatients. Ann Gen Psychiatry. 2010;9:16. doi:10.1186/1744-859X-9-1620398249
   PubMed Web of Science ®Google Scholar
• AlexopoulosGS, SireyJA, RauePJ, KanellopoulosD, ClarkTE, NovitchRS. Outcomes of depressed patients undergoing inpatient pulmonary rehabilitation. Am J Geriatr Psychiatry. 2006;14(5):466–475. doi:10.1097/01.JGP.0000199381.98971.d116670251
   PubMed Web of Science ®Google Scholar
• DursunogluN, KokturkN, BahaA, et al. Comorbidities and their impact on chronic obstructive pulmonary disease. Tuberk Toraks. 2016;64(4):289–298. doi:10.5578/tt.224528393718
   PubMedGoogle Scholar
• National Collaborating Centre for Mental H. National Institute for Health and Clinical Excellence: guidance In: Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological SocietyCopyright (c) The British Psychological Society & The Royal College of Psychiatrists; 2010:2010.
   Google Scholar
• BritainG; Excellence NIfC. Anxiety: Management of Anxiety (Panic Disorder, with or Without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. National Institute for Clinical Excellence; 2004.
   Google Scholar
• VolpatoE, BanfiP, RogersSM, PagniniF. Relaxation techniques for people with chronic obstructive pulmonary disease: a systematic review and a meta-analysis. Evid Based Complement Alternat Med. 2015;2015:628365. doi:10.1155/2015/62836526339268
   PubMed Web of Science ®Google Scholar
• YohannesAM, ConnollyMJ, BaldwinRC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2001;16(5):451–454. doi:10.1002/gps.46111376459
   PubMed Web of Science ®Google Scholar
• LacasseY, BeaudoinL, RousseauL, MaltaisF. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis. 2004;61(3):3. doi:10.4081/monaldi.2004.692
   Google Scholar
• EiserN, HarteR, SpirosK, PhillipsC, IsaacMT. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. Copd. 2005;2(2):233–241. doi:10.1081/COPD-5759617136950
   PubMedGoogle Scholar
• LightRW, MerrillEJ, DesparsJ, GordonGH, MutalipassiLR. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(7):1377–1380. doi:10.1001/archinte.1986.003601901550223521524
   PubMedGoogle Scholar
• BorsonS, McDonaldGJ, GayleT, DeffebachM, LakshminarayanS, VanTuinenC. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33(2):190–201. doi:10.1016/S0033-3182(92)71995-11557484
   PubMed Web of Science ®Google Scholar
• Depression in adults: recognition and management | guidance and guidelines | NICE. 2018; Available from: https://www.nice.org.uk/guidance/cg90. Accessed 316, 2020.
   Google Scholar
• YohannesAM, AlexopoulosGS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. Drugs Aging. 2014;31(7):483–492. doi:10.1007/s40266-014-0186-024902934
   PubMed Web of Science ®Google Scholar
• PriceD, SmallM, MilliganG, HigginsV, GilEG, EstruchJ. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603. doi:10.2147/COPD.S4857024348032
   PubMed Web of Science ®Google Scholar
• NunesDM, MotaRM, de Pontes NetoOL, PereiraED, de BruinVM, de BruinPF. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009;187(3):159–163. doi:10.1007/s00408-009-9147-519399553
   PubMed Web of Science ®Google Scholar
• ValipourA, LavieP, LothallerH, MikulicI, BurghuberOC. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med. 2011;12(4):367–372. doi:10.1016/j.sleep.2010.08.01721388878
   PubMed Web of Science ®Google Scholar
• BudhirajaR, SiddiqiTA, QuanSF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med. 2015;11(3):259–270. doi:10.5664/jcsm.454025700872
   PubMed Web of Science ®Google Scholar
• DodgeR, ClineMG, QuanSF. The natural history of insomnia and its relationship to respiratory symptoms. Arch Intern Med. 1995;155(16):1797–1800. doi:10.1001/archinte.1995.004301601450147654114
   PubMedGoogle Scholar
• ScharfSM, MaimonN, Simon-TuvalT, Bernhard-ScharfBJ, ReuveniH, TarasiukA. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;6:1–12. doi:10.2147/COPD21311688
   PubMed Web of Science ®Google Scholar
• McNicholasWT, VerbraeckenJ, MarinJM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev. 2013;22(129):365–375. doi:10.1183/09059180.0000321323997063
   PubMedGoogle Scholar
• OmachiTA, BlancPD, ClamanDM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13(5):476–483. doi:10.1016/j.sleep.2011.12.00722429651
   PubMed Web of Science ®Google Scholar
• RothT. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med. 2009;10(1):19–25. doi:10.1016/j.sleep.2008.06.00518693067
   PubMed Web of Science ®Google Scholar
• ChungWS, LaiCY, LinCL, KaoCH. Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study. Medicine (Baltimore). 2015;94(27):e1110. doi:10.1097/MD.000000000000111026166105
   PubMed Web of Science ®Google Scholar
• VozorisNT, FischerHD, WangX, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3):183–192. doi:10.1007/s40266-013-0056-123371396
   PubMed Web of Science ®Google Scholar
• VozorisNT, FischerHD, WangX, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44(2):332–340. doi:10.1183/09031936.0000801424743966
   PubMed Web of Science ®Google Scholar
• ZhangMW, HoRC, CheungMW, FuE, MakA. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2011;33(3):217–223. doi:10.1016/j.genhosppsych.2011.03.00921601717
   PubMed Web of Science ®Google Scholar
• HuberMB, WackerME, VogelmeierCF, LeidlR. Comorbid influences on generic health-related quality of life in COPD: a systematic review. PLoS One. 2015;10(7):e0132670. doi:10.1371/journal.pone.013267026168154
   PubMed Web of Science ®Google Scholar
• OmachiTA, KatzPP, YelinEH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med. 2009;122(8):778.e779–715. doi:10.1016/j.amjmed.2009.01.036
   PubMed Web of Science ®Google Scholar
• NgTP, NitiM, FonesC, YapKB, TanWC. Co-morbid association of depression and COPD: a population-based study. Respir Med. 2009;103(6):895–901. doi:10.1016/j.rmed.2008.12.01019136238
   PubMed Web of Science ®Google Scholar
• SalteK, TitlestadI, HallingA. Depression is associated with poor prognosis in patients with chronic obstructive pulmonary disease - a systematic review. Dan Med J. 2015;62(10):A5137.26441395
   PubMed Web of Science ®Google Scholar
• LechelerL, RichterM, FranzenDP, et al. The frequent and underrecognised co-occurrence of acute exacerbated COPD and depression warrants screening: a systematic review. Eur Respir Rev. 2017;26(144):144. doi:10.1183/16000617.0026-2017
   Web of Science ®Google Scholar
• PoolerA, BeechR. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis. 2014;9:315–330. doi:10.2147/COPD24729698
   PubMed Web of Science ®Google Scholar
• Al-shairK, DockryR, Mallia-MilanesB, KolsumU, SinghD, VestboJ. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med. 2009;103(10):1572–1579. doi:10.1016/j.rmed.2008.11.02119560330
   PubMed Web of Science ®Google Scholar
• RegvatJ, ZmitekA, VegnutiM, KosnikM, SuskovicS. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. J Int Med Res. 2011;39(3):1028–1038. doi:10.1177/14732300110390033821819737
   PubMed Web of Science ®Google Scholar
• KeatingA, LeeA, HollandAE. What prevents people with chronic obstructive pulmonary disease from attending pulmonary rehabilitation? A systematic review. Chron Respir Dis. 2011;8(2):89–99. doi:10.1177/147997231039375621596892
   PubMed Web of Science ®Google Scholar
• LeeSH, KimKU, LeeH, KimYS, LeeMK, ParkHK. Factors associated with low-level physical activity in elderly patients with chronic obstructive pulmonary disease. Korean J Intern Med. 2018;33(1):130–137. doi:10.3904/kjim.2016.09028602061
   PubMed Web of Science ®Google Scholar
• FritzscheA, ClamorA, von LeupoldtA. Effects of medical and psychological treatment of depression in patients with COPD–a review. Respir Med. 2011;105(10):1422–1433. doi:10.1016/j.rmed.2011.05.01421680167
   PubMed Web of Science ®Google Scholar
• AlbrechtJS, KhokharB, HuangT-Y, et al. Adherence and healthcare utilization among older adults with COPD and depression. Respir Med. 2017;129:53–58. doi:10.1016/j.rmed.2017.06.00228732836
   PubMed Web of Science ®Google Scholar
• SmithSM, SonegoS, KetchesonL, LarsonJL. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Respir Res. 2014;1(1):e000042. doi:10.1136/bmjresp-2014-000042
   PubMedGoogle Scholar
• DevineEC, PearcyJ. Meta-analysis of the effects of psychoeducational care in adults with chronic obstructive pulmonary disease. Patient Educ Couns. 1996;29(2):167–178. doi:10.1016/0738-3991(96)00862-29006233
   PubMed Web of Science ®Google Scholar
• TselebisA, PachiA, IliasI, et al. Strategies to improve anxiety and depression in patients with COPD: a mental health perspective. Neuropsychiatr Dis Treat. 2016;12:297–328. doi:10.2147/NDT26929625
   PubMed Web of Science ®Google Scholar
• Torres-SanchezI, ValenzaMC, Saez-RocaG, Cabrera-MartosI, Lopez-TorresI, Rodriguez-TorresJ. Results of a multimodal program during hospitalization in obese COPD exacerbated patients. COPD. 2016;13(1):19–25. doi:10.3109/15412555.2015.104342826418629
   PubMedGoogle Scholar
• SinghB, MielkeMM, ParsaikAK, et al. A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. JAMA Neurol. 2014;71(5):581–588. doi:10.1001/jamaneurol.2014.9424637951
   PubMed Web of Science ®Google Scholar
• DoddJW, CharltonRA, van den BroekMD, JonesPW. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest. 2013;144(1):119–127. doi:10.1378/chest.12-209923349026
   PubMed Web of Science ®Google Scholar
• ZhangX, CaiX, ShiX, et al. Chronic obstructive pulmonary disease as a risk factor for cognitive dysfunction: a meta-analysis of current studies. J Alzheimers Dis. 2016;52(1):101–111. doi:10.3233/JAD-15073526967208
   PubMed Web of Science ®Google Scholar
• OrtapamukH, NaldokenS. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med. 2006;20(2):99–106. doi:10.1007/BF298562116615418
   PubMed Web of Science ®Google Scholar
• ZhengGQ, WangY, WangXT. Chronic hypoxia-hypercapnia influences cognitive function: a possible new model of cognitive dysfunction in chronic obstructive pulmonary disease. Med Hypotheses. 2008;71(1):111–113. doi:10.1016/j.mehy.2008.01.02518331781
   PubMed Web of Science ®Google Scholar
• ChangSS, ChenS, McAvayGJ, TinettiME. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. J Am Geriatr Soc. 2012;60(10):1839–1846. doi:10.1111/j.1532-5415.2012.04171.x23035917
   PubMed Web of Science ®Google Scholar
• RaffaeleA-I, AndreaC, ClaudioP, et al. Drawing impairment predicts mortality in severe COPD. Chest. 2006;130(6):1687–1694. doi:10.1378/chest.130.6.168717166983
   PubMed Web of Science ®Google Scholar
• ThakurN, BlancPD, JulianLJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis. 2010;5:263–269. doi:10.2147/copd.s1068420856825
   PubMedGoogle Scholar
• PereiraED, VianaCS, TaunayTC, SalesPU, LimaJW, HolandaMA. Improvement of cognitive function after a three-month pulmonary rehabilitation program for COPD patients. Lung. 2011;189(4):279–285. doi:10.1007/s00408-011-9303-621656143
   PubMed Web of Science ®Google Scholar
• KozoraE, TranZV, MakeB. Neurobehavioral improvement after brief rehabilitation in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2002;22(6):426–430. doi:10.1097/00008483-200211000-0000812464831
   PubMedGoogle Scholar
• KennK, GloecklR, SoennichsenA, et al. Predictors of success for pulmonary rehabilitation in patients awaiting lung transplantation. Transplantation. 2015;99(5):1072–1077. doi:10.1097/TP.000000000000047225393161
   PubMed Web of Science ®Google Scholar
• StephensonA, SeitzDP, FischerHD, et al. Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study. Drugs Aging. 2012;29(3):213–223. doi:10.2165/11599480-000000000-0000022332932
   PubMed Web of Science ®Google Scholar
• RobertsMH, MapelDW, HartryA, Von WorleyA, ThomsonH. Chronic pain and pain medication use in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc. 2013;10(4):290–298. doi:10.1513/AnnalsATS.201303-040OC23952846
   PubMedGoogle Scholar
• BentsenSB, RustoenT, MiaskowskiC. Differences in subjective and objective respiratory parameters in patients with chronic obstructive pulmonary disease with and without pain. Int J Chron Obstruct Pulmon Dis. 2012;7:137–143. doi:10.2147/COPD22419861
   PubMed Web of Science ®Google Scholar
• ElkingtonH, WhiteP, Addington-HallJ, HiggsR, EdmondsP. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med. 2005;19(6):485–491. doi:10.1191/0269216305pm1056oa16218161
   PubMed Web of Science ®Google Scholar
• LohneV, HeerHC, AndersenM, MiaskowskiC, KongerudJ, RustoenT. Qualitative study of pain of patients with chronic obstructive pulmonary disease. Heart Lung. 2010;39(3):226–234. doi:10.1016/j.hrtlng.2009.08.00220457343
   PubMed Web of Science ®Google Scholar
• van Dam van IsseltEF, Groenewegen-SipkemaKH, Spruit-van EijkM, et al. Pain in patients with COPD: a systematic review and meta-analysis. BMJ Open. 2014;4(9):e005898. doi:10.1136/bmjopen-2014-005898
   PubMedGoogle Scholar
• BlindermanCD, HomelP, BillingsJA, TennstedtS, PortenoyRK. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manage. 2009;38(1):115–123. doi:10.1016/j.jpainsymman.2008.07.00619232893
   PubMed Web of Science ®Google Scholar
• BorgeCR, WahlAK, MoumT. Pain and quality of life with chronic obstructive pulmonary disease. Heart Lung. 2011;40(3):e90–101. doi:10.1016/j.hrtlng.2010.10.00921444112
   PubMedGoogle Scholar
• BentsenSB, RustoenT, MiaskowskiC. Prevalence and characteristics of pain in patients with chronic obstructive pulmonary disease compared to the Norwegian general population. J Pain. 2011;12(5):539–545. doi:10.1016/j.jpain.2010.10.01421549316
   PubMed Web of Science ®Google Scholar
• HajGhanbariB, GarlandSJ, RoadJD, ReidWD. Pain and physical performance in people with COPD. Respir Med. 2013;107(11):1692–1699. doi:10.1016/j.rmed.2013.06.01023845881
   PubMed Web of Science ®Google Scholar
• BorgeCR, WahlAK, MoumT. Association of breathlessness with multiple symptoms in chronic obstructive pulmonary disease. J Adv Nurs. 2010;66(12):2688–2700. doi:10.1111/j.1365-2648.2010.05447.x20825511
   PubMed Web of Science ®Google Scholar
• TanG, JensenMP, ThornbyJI, ShantiBF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133–137. doi:10.1016/j.jpain.2003.12.00515042521
   PubMed Web of Science ®Google Scholar
• RashiqS, DickBD. Factors associated with chronic noncancer pain in the Canadian population. Pain Res Manage. 2009;14(6):454–460. doi:10.1155/2009/919628
   PubMed Web of Science ®Google Scholar
• JanssenDJ, SpruitMA, Uszko-LencerNH, ScholsJM, WoutersEF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med. 2011;14(6):735–743. doi:10.1089/jpm.2010.047921510771
   PubMed Web of Science ®Google Scholar
• MapelDW, DutroMP, MartonJP, WoodruffK, MakeB. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11(1):43. doi:10.1186/1472-6963-11-4321345188
   PubMed Web of Science ®Google Scholar
• VerberktCA, van den Beuken-van EverdingenMHJ, ScholsJ, et al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J. 2017;50(5):5. doi:10.1183/13993003.01153-2017
   Web of Science ®Google Scholar
• EkstromM, BajwahS, BlandJM, CurrowDC, HussainJ, JohnsonMJ. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax. 2018;73(1):88–90. doi:10.1136/thoraxjnl-2016-20986828377491
   PubMed Web of Science ®Google Scholar
• EkstromMP, Bornefalk-HermanssonA, AbernethyAP, CurrowDC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445. doi:10.1136/bmj.g44524482539
   PubMed Web of Science ®Google Scholar
• GruberEM, TschernkoEM. Anaesthesia and postoperative analgesia in older patients with chronic obstructive pulmonary disease: special considerations. Drugs Aging. 2003;20(5):347–360. doi:10.2165/00002512-200320050-0000412696995
   PubMed Web of Science ®Google Scholar
• KaelinM, SwankA, BarnardK, AdamsK, BeachP, NewmanJ. Physical fitness and quality of life outcomes in a pulmonary rehabilitation program utilizing symptom limited interval training and resistance training. J Exerc Physiol Online. 2001;4:3.
   Google Scholar
• BoueriFM, Bucher-BartelsonBL, GlennKA, MakeBJ. Quality of life measured with a generic instrument (Short Form-36) improves following pulmonary rehabilitation in patients with COPD. Chest. 2001;119(1):77–84. doi:10.1378/chest.119.1.7711157587
   PubMed Web of Science ®Google Scholar
• De TorresJP, Pinto-PlataV, IngenitoE, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest. 2002;121(4):1092–1098. doi:10.1378/chest.121.4.109211948037
   PubMed Web of Science ®Google Scholar
• YohannesAM, ErshlerWB. Anemia in COPD: a systematic review of the prevalence, quality of life, and mortality. Respir Care. 2011;56(5):644–652. doi:10.4187/respcare.0100221276321
   PubMed Web of Science ®Google Scholar
• SilverbergDS, MorR, WeuMT, SchwartzD, SchwartzIF, CherninG. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med. 2014;14:24. doi:10.1186/1471-2466-14-2424564844
   PubMed Web of Science ®Google Scholar
• KrishnanG, GrantBJ, MutiPC, et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med. 2006;6(1):23. doi:10.1186/1471-2466-6-2316953872
   PubMedGoogle Scholar
• ChambellanA, ChailleuxE, SimilowskiT. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005;128(3):1201–1208. doi:10.1378/chest.128.3.120116162707
   PubMed Web of Science ®Google Scholar
• PortilloK, BeldaJ, AntonP, CasanP. [High frequency of anemia in COPD patients admitted in a tertiary hospital]. Rev Clin Esp. 2007;207(8):383–387. doi:10.1157/1310875517688864
   PubMed Web of Science ®Google Scholar
• VasquezA, LogomarsinoJV. Anemia in chronic obstructive pulmonary disease and the potential role of iron deficiency. Copd. 2016;13(1):100–109. doi:10.3109/15412555.2015.104351926418826
   PubMedGoogle Scholar
• BarbaR, de CasasolaGG, MarcoJ, et al. Anemia in chronic obstructive pulmonary disease: a readmission prognosis factor. Curr Med Res Opin. 2012;28(4):617–622. doi:10.1185/03007995.2012.67531822409165
   PubMed Web of Science ®Google Scholar
• HalpernMT, ZilberbergMD, SchmierJK, LauEC, ShorrAF. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc. 2006;4(1):17. doi:10.1186/1478-7547-4-1717042950
   PubMedGoogle Scholar
• CoteC, ZilberbergMD, ModySH, DordellyLJ, CelliB. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29(5):923–929. doi:10.1183/09031936.0013710617251227
   PubMed Web of Science ®Google Scholar
• Haja MydinH, MurphyS, ClagueH, SridharanK, TaylorIK. Anemia and performance status as prognostic markers in acute hypercapnic respiratory failure due to chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:151–157. doi:10.2147/COPD.S3940323658480
   PubMed Web of Science ®Google Scholar
• Martinez-RiveraC, PortilloK, Munoz-FerrerA, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. Copd. 2012;9(3):243–250. doi:10.3109/15412555.2011.64713122360381
   PubMedGoogle Scholar
• RasmussenL, ChristensenS, Lenler-PetersenP, JohnsenSP. Anemia and 90-day mortality in COPD patients requiring invasive mechanical ventilation. Clin Epidemiol. 2010;3:1–5. doi:10.2147/CLEP.S1288521326654
   PubMedGoogle Scholar
• CopurAS, FulambarkerA, MolnarJ, et al. Role of anemia in home oxygen therapy in chronic obstructive pulmonary disease patients. Am J Ther. 2015;22(5):361–366. doi:10.1097/MJT.0b013e3182785f7c23567789
   PubMed Web of Science ®Google Scholar
• SchonhoferB, BohrerH, KohlerD. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia. 1998;53(2):181–184. doi:10.1046/j.1365-2044.1998.00275.x9534644
   PubMed Web of Science ®Google Scholar
• Graat-VerboomL, WoutersEF, SmeenkFW, van den BorneBE, LundeR, SpruitMA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209–218. doi:10.1183/09031936.5013040819567604
   PubMed Web of Science ®Google Scholar
• AlmagroP, Lopez GarciaF, CabreraFJ, et al. [Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study]. Rev Clin Esp. 2010;210(3):101–108. doi:10.1016/j.rce.2009.12.00220226938
   PubMed Web of Science ®Google Scholar
• SilvaDR, CoelhoAC, DumkeA, et al. Osteoporosis prevalence and associated factors in patients with COPD: a cross-sectional study. Respir Care. 2011;56(7):961–968. doi:10.4187/respcare.0105621352667
   PubMed Web of Science ®Google Scholar
• Graat-VerboomL, SpruitMA, van den BorneBE, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. Respir Med. 2009;103(8):1143–1151. doi:10.1016/j.rmed.2009.02.01419304474
   PubMed Web of Science ®Google Scholar
• LeeSH, KwonHY. Prevalence of Osteoporosis in Korean patients with chronic obstructive pulmonary disease and their health-related quality of life according to the Korea National Health and Nutrition Examination Survey 2008–2011. J Bone Metab. 2017;24(4):241–248. doi:10.11005/jbm.2017.24.4.24129259964
   PubMedGoogle Scholar
• LinC-W, Chen-Y-Y, ChenY-J, LiangC-Y, LinM-S, ChenW. Prevalence, risk factors, and health-related quality of life of osteoporosis in patients with COPD at a community hospital in Taiwan. Int J Chron Obstruct Pulmon Dis. 2015;10:1493–1500. doi:10.2147/COPD.S8543226251589
   PubMed Web of Science ®Google Scholar
• RommeEA, MurchisonJT, EdwardsLD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res. 2013;28(6):1369–1377. doi:10.1002/jbmr.187323361992
   PubMed Web of Science ®Google Scholar
• MalinovschiA, MasoeroM, BellocchiaM, et al. Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients. Respir Res. 2014;15:131. doi:10.1186/s12931-014-0131-025496239
   PubMed Web of Science ®Google Scholar
• Pascual-GuardiaS, Badenes-BonetD, Martin-OntiyueloC, et al. Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures. Int J Chron Obstruct Pulmon Dis. 2017;12:1837–1845. doi:10.2147/COPD28684906
   PubMed Web of Science ®Google Scholar
• HattiholiJ, GaudeGS. Prevalence and correlates of osteoporosis in chronic obstructive pulmonary disease patients in India. Lung India. 2014;31(3):221–227. doi:10.4103/0970-2113.13575925125807
   PubMedGoogle Scholar
• KiyokawaH, MuroS, OgumaT, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD. 2012;9(3):235–242. doi:10.3109/15412555.2011.65024322360380
   PubMedGoogle Scholar
• HarrisonRA, SiminoskiK, VethanayagamD, MajumdarSR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res. 2007;22(3):447–457. doi:10.1359/jbmr.06120217181402
   PubMed Web of Science ®Google Scholar
• HornikxM, Van RemoortelH, DemeyerH, et al. The influence of comorbidities on outcomes of pulmonary rehabilitation programs in patients with COPD: a systematic review. Biomed Res Int. 2013;2013:146148. doi:10.1155/2013/14614824490146
   PubMed Web of Science ®Google Scholar
• AmicheMA, AlbaumJM, TadrousM, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709–1718. doi:10.1007/s00198-015-3455-926694595
   PubMed Web of Science ®Google Scholar
• MattishentK, ThavarajahM, BlancoP, GilbertD, WilsonAM, LokeYK. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs. 2014;74(5):539–547. doi:10.1007/s40265-014-0202-z24659375
   PubMed Web of Science ®Google Scholar
• LokeYK, CavallazziR, SinghS. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699–708. doi:10.1136/thx.2011.16002821602540
   PubMed Web of Science ®Google Scholar
• MineoTC, AmbrogiV, MineoD, FabbriA, FabbriniE, MassoudR. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest. 2005;127(6):1960–1966. doi:10.1378/chest.127.6.196015947308
   PubMed Web of Science ®Google Scholar
• AllenCS, YeungJH, VandermeerB, HomikJ. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:Cd001347.27706804
   PubMedGoogle Scholar
• CasanovaC, BaudetJS, Del Valle VelascoM, et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J. 2004;23(6):841–845. doi:10.1183/09031936.04.0010700415218995
   PubMed Web of Science ®Google Scholar
• SakaeTM, PizzichiniMM, TeixeiraPJ, SilvaRM, TrevisolDJ, PizzichiniE. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol. 2013;39(3):259–271. doi:10.1590/S1806-3713201300030000223857694
   PubMed Web of Science ®Google Scholar
• KimJ, LeeJH, KimY, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med. 2013;13:51. doi:10.1186/1471-2466-13-5123927016
   PubMed Web of Science ®Google Scholar
• KempainenRR, SavikK, WhelanTP, DunitzJM, HerringtonCS, BillingsJL. High prevalence of proximal and distal gastroesophageal reflux disease in advanced COPD. Chest. 2007;131(6):1666–1671. doi:10.1378/chest.06-226417400682
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, MullerovaH, LocantoreN, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013;14(1):79. doi:10.1186/1465-9921-14-7923899210
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• López GarcíaFPLF. Enfermedades digestivas y enfermedad pulmonar obstructiva crónica. [Digestive diseases and chronic obstructive pulmonary disease]. Med Clin (Barc). 2010;11:13–16. Spanish.
   Google Scholar
• RizkallahJ, ManSFP, SinDD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135(3):786–793. doi:10.1378/chest.08-151618812453
   PubMed Web of Science ®Google Scholar
• TeradaK, MuroS, SatoS, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008;63(11):951–955. doi:10.1136/thx.2007.09285818535116
   PubMed Web of Science ®Google Scholar
• TakadaK, MatsumotoS, KojimaE, et al. Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. Respir Med. 2011;105(10):1531–1536. doi:10.1016/j.rmed.2011.03.00921454063
   PubMed Web of Science ®Google Scholar
• Lopez-EncuentraA, AstudilloJ, CerezalJ, et al. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg. 2005;27(1):8–13. doi:10.1016/j.ejcts.2004.09.01015736303
   PubMed Web of Science ®Google Scholar
• MartinezC, OkajimaY, MurrayS, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res. 2014;15:62. doi:10.1186/1465-9921-15-6224894541
   PubMed Web of Science ®Google Scholar
• IngebrigtsenTS, MarottJL, VestboJ, NordestgaardBG, HallasJ, LangeP. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015;20(1):101–107. doi:10.1111/resp.1242025297724
   PubMed Web of Science ®Google Scholar
• LiangBM, FengYL. Association of gastroesophageal reflux disease symptoms with stable chronic obstructive pulmonary disease. Lung. 2012;190(3):277–282. doi:10.1007/s00408-011-9365-522258420
   PubMed Web of Science ®Google Scholar
• Garcia RodriguezLA, RuigomezA, Martin-MerinoE, JohanssonS, WallanderM-A. Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest. 2008;134(6):1223–1230. doi:10.1378/chest.08-090218689591
   PubMed Web of Science ®Google Scholar
• Del GrandeLM, HerbellaFA, BigataoAM, JardimJR, PattiMG. Inhaled beta agonist bronchodilator does not affect trans-diaphragmatic pressure gradient but decreases lower esophageal sphincter retention pressure in patients with Chronic Obstructive Pulmonary Disease (COPD) and Gastroesophageal Reflux Disease (GERD). J Gastrointest Surg. 2016;20(10):1679–1682. doi:10.1007/s11605-016-3192-127350150
   PubMed Web of Science ®Google Scholar
• CuiY, DevillierP, KuangX, et al. Tiotropium reduction of lung inflammation in a model of chronic gastro-oesophageal reflux. Eur Respir J. 2010;35(6):1370–1376. doi:10.1183/09031936.0013990919926736
   PubMed Web of Science ®Google Scholar
• Fernández-RuizM, Guerra-ValesJ. Comorbilidad digestiva y hepática en la EPOC [Digestive and liver comorbidity in COPD]. Rev Clin Esp. 2007;207(Supl1):40–46. Spanish
   Google Scholar
• KatzPO, GersonLB, VelaMF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328; quiz 329. doi:10.1038/ajg.2012.444
   Web of Science ®Google Scholar
• BoereeMJ, PetersFT, PostmaDS, KleibeukerJH. No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. Eur Respir J. 1998;11(5):1070–1074. doi:10.1183/09031936.98.110510709648957
   PubMed Web of Science ®Google Scholar
• PoeRH, KallayMC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest. 2003;123(3):679–684. doi:10.1378/chest.123.3.67912628862
   PubMed Web of Science ®Google Scholar
• XiongW, ZhangQS, ZhaoW, DingW, LiuJM, ZhaoYF. A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease. Int J Exp Pathol. 2016;97(2):107–113. doi:10.1111/iep.1217327135904
   PubMed Web of Science ®Google Scholar
• PenaX, Van Den EyndeE, MeneE, RecioJ. EPOC y enfermedad cardiovascular [COPD and cardiovascular disease]. Rev Clin Esp. 2007;207(Supl1):14–21. Spanish.
   Google Scholar
• GunenH, GulbasG, InE, YetkinO, HacievliyagilSS. Venous thromboemboli and exacerbations of COPD. Eur Respir J. 2010;35(6):1243–1248. doi:10.1183/09031936.0012090919926740
   PubMed Web of Science ®Google Scholar
• DuanSC, YangYH, LiXY, et al. Prevalence of deep venous thrombosis in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl). 2010;123(12):1510–1514.20819502
   PubMed Web of Science ®Google Scholar
• BørvikT, BrækkanSK, EngaK, et al. COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J. 2016;47(2):473–481. doi:10.1183/13993003.00402-201526585434
   PubMed Web of Science ®Google Scholar
• KimV, GoelN, GangarJ, et al. Risk factors for venous thromboembolism in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2014;1(2):239–249. doi:10.15326/jcopdf.1.2.2014.0133#sthash.pvwPnxaI.dpuf25844397
   PubMedGoogle Scholar
• BurgelPR, EscamillaR, PerezT, et al. Impact of comorbidities on COPD-specific health-related quality of life. Respir Med. 2013;107(2):233–241. doi:10.1016/j.rmed.2012.10.00223098687
   PubMed Web of Science ®Google Scholar
• WangTS, MaoYM, SunYM, LouYJ. [Pulmonary embolism in patients with chronic obstructive pulmonary disease exacerbations of unknown origin: clinical characteristics and risk factors]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(4):259–263.22781197
   PubMedGoogle Scholar
• BertolettiL, QuenetS, LaporteS, et al. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res. 2013;14:75. doi:10.1186/1465-9921-14-7523865769
   PubMed Web of Science ®Google Scholar
• SteinPD, MattaF. Vena cava filters in hospitalised patients with chronic obstructive pulmonary disease and pulmonary embolism. Thromb Haemost. 2013;109(5):897–900. doi:10.1160/TH13-01-000623467701
   PubMed Web of Science ®Google Scholar
• PiazzaG, GoldhaberSZ, KrollA, GoldbergRJ, EmeryC, SpencerFA. Venous thromboembolism in patients with chronic obstructive pulmonary disease. Am J Med. 2012;125(10):1010–1018. doi:10.1016/j.amjmed.2012.03.00722884176
   PubMed Web of Science ®Google Scholar
• FraisseF, HolzapfelL, CoulandJM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1109–1114. doi:10.1164/ajrccm.161.4.980702510764298
   PubMed Web of Science ®Google Scholar
• IncalziRA, CorsonelloA, PedoneC, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest. 2010;137(4):831–837. doi:10.1378/chest.09-171019903974
   PubMed Web of Science ®Google Scholar
• TerzanoC, ContiV, Di StefanoF, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188(4):321–329. doi:10.1007/s00408-009-9222-y20066539
   PubMed Web of Science ®Google Scholar
• Diez ManglanoJ, Bernabeu-WittelM, Escalera-ZalvideA, et al. [Comorbidity, discapacity and mortality in patients with multiple conditions and chronic obstructive pulmonary disease]. Rev Clin Esp. 2011;211(10):504–510. doi:10.1016/j.rce.2011.04.00621982043
   PubMed Web of Science ®Google Scholar
• MapelDW, MartonJP. Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:127–134. doi:10.2147/COPD23515180
   PubMed Web of Science ®Google Scholar
• HanlyP. Sleep apnea and daytime sleepiness in end-stage renal disease. Semin Dial. 2004;17(2):109–114. doi:10.1111/j.0894-0959.2004.17206.x15043611
   PubMed Web of Science ®Google Scholar
• SinganayagamA, SchembriS, ChalmersJD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81–89. doi:10.1513/AnnalsATS.201208-043OC23607835
   PubMedGoogle Scholar
• van GestelYR, ChoncholM, HoeksSE, et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol Dial Transplant. 2009;24(9):2763–2767. doi:10.1093/ndt/gfp17119369691
   PubMed Web of Science ®Google Scholar
• FabbianF, De GiorgiA, ManfrediniF, et al. Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: a single-center Italian study. Int Urol Nephrol. 2016;48(7):1121–1127. doi:10.1007/s11255-016-1272-527020445
   PubMed Web of Science ®Google Scholar
• FedeliU, De GiorgiA, GennaroN, et al. Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. Int J Chron Obstruct Pulmon Dis. 2017;12:443–450. doi:10.2147/COPD28184156
   PubMedGoogle Scholar
• IncalziRA, CorsonelloA, PedoneC, BattagliaS, PaglinoG, BelliaV. Chronic renal failure: a neglected comorbidity of COPD. Chest. 2010;137(4):831–837. doi:10.1378/chest.09-171019903974
   PubMed Web of Science ®Google Scholar
• AlcazarR, EgocheagaMI, OrteL, et al. [SEN-SEMFYC consensus document on chronic kidney disease]. Nefrologia. 2008;28(3):273–282.18590493
   PubMed Web of Science ®Google Scholar
• Diez HerranzA. [COPD and lung cancer: practical implications]. Arch Bronconeumol. 2001;37(5):240–247. doi:10.1016/s0300-2896(01)75061-211412516
   PubMed Web of Science ®Google Scholar
• Wasswa-KintuS, GanWQ, ManSF, ParePD, SinDD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60(7):570–575. doi:10.1136/thx.2004.03713515994265
   PubMed Web of Science ®Google Scholar
• ManninoDM, AguayoSM, PettyTL, ReddSC. Low lung function and incident lung cancer in the United States: data from the first national health and nutrition examination survey follow-up. Arch Intern Med. 2003;163(12):1475–1480. doi:10.1001/archinte.163.12.147512824098
   PubMedGoogle Scholar
• WilsonDO, WeissfeldJL, BalkanA, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178(7):738–744. doi:10.1164/rccm.200803-435OC18565949
   PubMed Web of Science ®Google Scholar
• FabbriLM, LuppiF, BegheB, RabeKF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–212. doi:10.1183/09031936.0011430718166598
   PubMed Web of Science ®Google Scholar
• de-TorresJP, WilsonDO, Sanchez-SalcedoP, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med. 2015;191(3):285–291. doi:10.1164/rccm.201407-1210OC25522175
   PubMed Web of Science ®Google Scholar
• ParimonT, ChienJW, BrysonCL, McDonellMB, UdrisEM, AuDH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(7):712–719. doi:10.1164/rccm.200608-1125OC17185647
   PubMed Web of Science ®Google Scholar
• KiriVA, FabbriLM, DavisKJ, SorianoJB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med. 2009;103(1):85–90. doi:10.1016/j.rmed.2008.07.02418793832
   PubMed Web of Science ®Google Scholar
• YaoR, WangY, LemonWJ, LubetRA, YouM. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene. 2004;23(46):7746–7752. doi:10.1038/sj.onc.120798515361829
   PubMed Web of Science ®Google Scholar
• LimE, BaldwinD, BecklesM, et al. Guidelines on the radical management of patients with lung cancer. Thorax. 2010;65(Suppl 3):iii1–27. doi:10.1136/thx.2010.145938.20940263
   PubMed Web of Science ®Google Scholar